Telor Ophthalmic Pharmaceuticals Inc. other research news
TELR (Woburn, Mass.) said it had reached a decision on the future of its program to develop Tekron for controlling intraocular pressure associated with glaucoma and ocular hypertension. The company announced in September that in its Phase IIa trial, the topical formulation of the active ingredient, ethacrynic acid, was associated with unacceptable eye irritation.
TELR has decided on a two-pronged approach. It will proceed with development of an eyedrop formulation of Tekron, using new excipients. In a glaucomatous monkey model, the new formulation reduced elevated intraocular pressure by up to 10 mm Hg, the same reductions or slightly better than those seen with the original ointment formulation, according to Chief Scientific Officer Art Neufeld. ...